טוען...
Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
Myelodysplastic syndromes and acute myeloid leukemia with TP53 mutations are characterized by frequent relapses, poor or short responses, and poor survival with the currently available therapies including chemotherapy and 5-azacitidine (AZA). PRIMA-1(Met)(APR-246,APR) is a methylated derivative of P...
שמור ב:
| הוצא לאור ב: | Haematologica |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Ferrata Storti Foundation
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7271596/ https://ncbi.nlm.nih.gov/pubmed/31488557 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.218453 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|